Sutro Biopharma, Inc. Common Stock STRO
i
Market dataready · fetched 2026-11-12T00:46:46.290Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:02.204468415Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-12T00:46:45.704254+00:00
Sutro Biopharma, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 37.73 | 600.2% | 275.0% | 8.07 | 283.1% | 29.6% |
| 25Δ | 34.18 | 586.6% | 242.8% | 8.68 | 326.1% | 28.6% |
| 30Δ | 30.63 | 572.9% | 210.5% | 9.30 | 369.1% | 27.6% |
| 35Δ | 27.08 | 559.3% | 178.3% | 9.91 | 412.2% | 26.6% |
| 40Δ | 23.53 | 545.7% | 146.0% | 10.26 | 390.0% | 24.0% |
| 45Δ | 19.98 | 532.0% | 113.7% | 10.56 | 357.2% | 21.1% |
| 50Δ | 16.43 | 518.4% | 81.5% | 10.86 | 324.4% | 18.2% |
| 55Δ | 12.88 | 504.7% | 49.2% | 11.16 | 291.6% | 15.4% |
| 60Δ | 11.08 | 431.9% | 32.1% | 11.45 | 258.8% | 12.5% |
| 65Δ | 11.75 | 226.0% | 9.7% | |||
| 70Δ | 12.05 | 193.2% | 6.8% | |||
| 75Δ | 12.35 | 160.4% | 3.9% | |||
| 80Δ | 12.83 | 142.0% | 2.2% | |||
20Δ
- Pseudo strike
- 37.73
- IV
- 600.2%
- B/E move
- 275.0%
- Pseudo strike
- 8.07
- IV
- 283.1%
- B/E move
- 29.6%
25Δ
- Pseudo strike
- 34.18
- IV
- 586.6%
- B/E move
- 242.8%
- Pseudo strike
- 8.68
- IV
- 326.1%
- B/E move
- 28.6%
30Δ
- Pseudo strike
- 30.63
- IV
- 572.9%
- B/E move
- 210.5%
- Pseudo strike
- 9.30
- IV
- 369.1%
- B/E move
- 27.6%
35Δ
- Pseudo strike
- 27.08
- IV
- 559.3%
- B/E move
- 178.3%
- Pseudo strike
- 9.91
- IV
- 412.2%
- B/E move
- 26.6%
40Δ
- Pseudo strike
- 23.53
- IV
- 545.7%
- B/E move
- 146.0%
- Pseudo strike
- 10.26
- IV
- 390.0%
- B/E move
- 24.0%
45Δ
- Pseudo strike
- 19.98
- IV
- 532.0%
- B/E move
- 113.7%
- Pseudo strike
- 10.56
- IV
- 357.2%
- B/E move
- 21.1%
50Δ
- Pseudo strike
- 16.43
- IV
- 518.4%
- B/E move
- 81.5%
- Pseudo strike
- 10.86
- IV
- 324.4%
- B/E move
- 18.2%
55Δ
- Pseudo strike
- 12.88
- IV
- 504.7%
- B/E move
- 49.2%
- Pseudo strike
- 11.16
- IV
- 291.6%
- B/E move
- 15.4%
60Δ
- Pseudo strike
- 11.08
- IV
- 431.9%
- B/E move
- 32.1%
- Pseudo strike
- 11.45
- IV
- 258.8%
- B/E move
- 12.5%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.75
- IV
- 226.0%
- B/E move
- 9.7%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.05
- IV
- 193.2%
- B/E move
- 6.8%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.35
- IV
- 160.4%
- B/E move
- 3.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.83
- IV
- 142.0%
- B/E move
- 2.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 154.86% | |
| 144.88% | |
| 175.57% | |
| 190.07% | |
| 224.23% | |
| 226.52% | |
| 219.88% | |
| 228.83% |
Biotechnology
STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. The company is…
More →SVRA
Description unavailable
More →SYRE
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody…
More →TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare…
More →TARS
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions.…
More →TECH
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is…
More →